◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: medium Compound SKIP-FOR-NOW HIGH

Dianabol

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict SKIP-FOR-NOW HIGH

For a 20-year-old MMA athlete + business owner with an intact HPG axis at peak endogenous testosterone production, Dianabol fails on every axis — (1) zero medical indication; the user has no hypogonadism, no catabolic illness, no anemia, no muscle-wasting condition; (2) hepatotoxicity (LiverTox Likelihood A) is the dominant concern — cholestatic jaundice, peliosis hepatis, and rare hepatic adenoma are documented at chronic 4-6+ week oral exposure, and even a 'safe' 4-week kickstart cycle produces measurable ALT/AST elevation, HDL crash 30-50%, LDL elevation, BP creep, and HPG-axis suppression; (3) MMA-context cosmetic + performance penalties — water retention adds bad weight for combat sport, pre-competition water-cut is harder, gyno from 17α-methylestradiol is cosmetically devastating and may require surgical correction; (4) WADA-banned, USADA-banned (UFC), most state athletic commissions test — potential career-ending sanction; (5) legality — Schedule III felony possession in US, no legitimate source for retail; UGL product carries counterfeit + mislabeling + contamination risk; (6) reversibility — most gain is water/glycogen and reverses post-cycle; HPG-axis recovery 6-12 weeks even from a short cycle. Verdict would only flip in a counterfactual where (a) the user developed a medically diagnosed catabolic-wasting state, AND (b) injectable testosterone replacement was contraindicated or insufficient — neither is on any realistic horizon. Even then, Dianabol is strictly dominated by injectable testosterone esters (T-cypionate / T-enanthate) for hepatic safety, and by oxandrolone for any mild oral-AAS use case.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • ★20-25, brain-priority, MMA athlete (the user)
    SKIP-AT-

    No medical indication; peak endogenous testosterone; combat sport drug-tested; hepatotoxicity is the dominant concern; water retention is a combat-sport liability; WADA + state athletic commission ban makes any positive test career-ending. Confidence HIGH.

  • 25-30, gym-focused, untested
    OPTIONAL-EXPERIMENT

    If insistent on AAS use, Dianabol's 1960s-2026 track record makes it a "known quantity" oral. Still a 4-6 week cap, still hepatotoxic, still requires injectable T base, still requires anastrozole + harm-reduction adjuncts. Strictly dominated by injectable-only protocols (T-enanthate alone with no oral kickstart) for hepatic safety.

  • 30-50, executive maintenance
    SKIP

    No good rationale. Use injectable T-enanthate at TRT dose if labs warrant, with proper Rx + monitoring.

  • 50+, established hypogonadism, post-andropause
    SKIP

    Injectable T-enanthate / cypionate at TRT dose is the right tool. Dianabol adds hepatic + cardiovascular risk without benefit.

  • Female athlete, any age
    SKIP-PERMANENT

    Virilization risk from any AAS is high; methandienone's androgenic signal at supraphysiologic dose causes irreversible voice deepening, clitoral enlargement, hair patterning. Oxandrolone is the only oral AAS with any defensible women's-athlete use case.

  • Drug-tested at any tier (WADA, USADA, NCAA, employer, military, state athletic commission)
    SKIP-PERMANENT

    Detection windows for methandienone metabolites extend 4-8 weeks post-discontinuation; long-term metabolites (LTMs like 18-nor-17β-hydroxymethyl-17α-methyl-2-oxa-5α-androstane) are detectable for months. Modern WADA labs target these. Career risk dwarfs benefit.

  • Bodybuilder, untested, accepting full risk
    OPTIONAL-USE

    This is the historical user base. Not a recommendation, just an honest framing of the original use case. Dianabol's place in this niche is well-defined; for everyone else, it's outside the toolkit.

  • Liver disease (any), Gilbert's, prior DILI history, hepatotoxic-drug history
    HARD BLOCK

    Compounded hepatic risk; not worth running.

  • Cardiovascular risk factors (HTN, dyslipidemia, family CAD)
    HARD BLOCK

    Lipid + BP disruption compounds existing risk.

  • Mood disorder (bipolar, psychosis history, severe anxiety)
    HARD BLOCK

    AAS-induced mood lability + aggression risk.

▸ Subjective experience (deep)

Per bodybuilding-era + modern UGL community reports at 20-50 mg/day:

  • Day 3-7: Strength surge, increased appetite, scale weight up 4-8 lb (mostly water + glycogen), euphoria / aggression for some, BP creep. Many users report subjective sense of "feeling huge" by end of week 1.
  • Week 2-4: Peak strength gains, "pumps" described as painful at the working set. ALT/AST climbing, HDL falling, BP elevated. E2 rising — gyno onset possible (sensitive nipples → palpable lump under areola).
  • Week 4-6: Diminishing additional gains. Hepatic burden compounds — bilirubin may rise; signs of cholestasis (dark urine, light stool, pruritus without rash) demand immediate cessation.
  • Post-cycle: Water/glycogen weight drops fast — 30-50% of scale gain reverses in 2-4 weeks. HPG axis suppressed; recovery 6-12 weeks typical, longer if poorly managed.
  • Mood/cognitive: Some users report aggressive "Dbol rage" — disinhibition, conflict-seeking, sleep disruption. Others report euphoria + confidence boost. Highly individual.
  • Sleep: Generally disrupted — water retention, BP elevation, and direct CNS arousal contribute. Sleep quality drops measurably for most users on cycle.
  • Libido: High during cycle (androgenic surge), potentially low post-cycle during HPG recovery (the "Dbol blues").

Reality check for combat sport: Water retention is a liability — adds bad mass that won't pass weigh-in cleanly, makes pre-fight water cuts harder, raises BP at altitude / under cardio load. The strength gain is real but a meaningful fraction is wash-out post-cycle. For an MMA athlete, the cosmetic + performance penalties stack against the gain.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: Real and rapid for the anabolic signal — strength gains plateau by week 4-5 even at constant dose. Receptor downregulation + HPG suppression. There is no protocol to "blast through" the plateau without dose escalation, which compounds toxicity non-linearly.
  • Cycle length: NEVER >6 weeks oral. Most prudent runs are 4 weeks. Some run 6 weeks at lower dose (20 mg/day). The hepatic-injury risk curve steepens past 4-6 weeks.
  • Washout: Minimum 12 weeks before next 17αAA exposure of any kind. Liver enzymes should return to baseline; lipid panel should normalize; HPG axis should recover.
  • Bridging / "blast and cruise": Some bodybuilding protocols run continuous orals. Don't. Acute hepatic failure cases overwhelmingly cluster in continuous-oral users.
  • Re-cycling: Possible in principle but each oral exposure compounds cumulative hepatic burden. The user should run zero cycles. Even adult bodybuilding consensus is 1-2 oral cycles per year max.
▸ Stacking deep dive

Synergistic (in bodybuilding context — none recommended for the user)

  • testosterone-enanthate / testosterone-cypionate. Standard kickstart pair. Dianabol weeks 1-4 (rapid early gains), Test-E 400-500 mg/week weeks 1-12 (sustained anabolic). The synergy is real (mechanism-additive AR signaling); it does not address the hepatic risk Dianabol carries on its own.
  • anastrozole. Mechanistically required to control 17α-methylestradiol-driven gyno + water retention. 0.25-0.5 mg EOD on cycle. Dose by symptoms; over-suppression of E2 in young men crashes joint health, libido, lipids.
  • Aromatase inhibitor or SERM (tamoxifen) for gyno reversal. If gyno onset, switch from anastrozole to tamoxifen 10-20 mg/day for 4-8 weeks. Surgical excision if persistent.

Avoid stacking with

  • Other 17α-alkylated AAS (oxandrolone, stanozolol, methyltestosterone, oxymetholone, fluoxymesterone, danazol, trenbolone — note trenbolone is 17β-hydroxy not 17α, but its A-ring methyl makes it functionally hepatotoxic). Never stack two oral 17αAAs. Acute hepatic failure cluster.
  • Alcohol. Dramatic compounding of hepatic load.
  • Acetaminophen / paracetamol at chronic dose. Additive hepatotoxicity.
  • Statins. Compounding lipid disruption + hepatic load.
  • Anticoagulants (warfarin, DOACs). AAS class potentiates anticoagulation; methandienone-specific case reports of warfarin INR spike.
  • NSAIDs (chronic). Compounding hepatic + renal load.

Harm-reduction adjuncts (narrow risk, do not eliminate it)

  • tudca — Tauroursodeoxycholic acid 500-1500 mg/day. Most commonly cited liver-protection adjunct. Mechanism: improves bile flow, displaces hydrophobic bile acids, reduces cholestatic stress. Animal + small human data in cholestatic disease support the mechanism. No human RCT in AAS users specifically. Reduces ALT/AST modestly on cycle but does not reverse the structural risk.
  • NAC (N-acetylcysteine) 600-1800 mg/day. Glutathione precursor; supports phase-II hepatic detoxification. Same caveat — risk-narrowing, not risk-eliminating. Best paired with TUDCA.
  • Milk thistle (silymarin) 200-400 mg/day. Older harm-reduction standard. Weaker evidence than TUDCA/NAC. Doesn't hurt; doesn't dramatically help.
  • Curcumin / phytosome curcumin. Anti-inflammatory + mild hepatoprotective signal in animal models. Adjunct only.
  • Krill oil / omega-3. Supports lipid panel during cycle (partial offset of HDL crash).

The honest framing: TUDCA + NAC is the most that bodybuilding harm-reduction culture has converged on. It narrows the risk envelope but doesn't change the structural fact that you're running a 17α-alkylated steroid. No off-cycle support makes Dianabol "safe" for a user with no medical indication.

Neutral / safe co-administration

  • The user's existing V4 stack (DHA, Magtein, Citicoline, NAC, PS, Mg Glycinate, Curcumin Phytosome, Rhodiola, L-Theanine, Glycine/L-Tryptophan, D3+K2, Beta-Alanine, Vit C, creatine) — none would directly increase Dianabol risk; some (NAC, curcumin, omega-3) are part of the harm-reduction floor.
  • Modafinil — neutral. No known interaction.
▸ Drug interactions deep dive
  • CYP450: Methandienone is metabolized via hepatic 6β-hydroxylation (CYP3A4) and 4-ene-3-one A-ring reduction. CYP3A4 inducers (rifampicin, carbamazepine, St. John's wort) may reduce levels; CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit) may raise levels. Clinical significance modest at typical doses.
  • Anticoagulants: Potentiates warfarin and likely DOACs. Monitor INR closely if combined.
  • Insulin / oral diabetic agents: Reduces insulin sensitivity; may require dose adjustment for diabetics.
  • Cyclosporine / tacrolimus: AAS may raise levels via CYP3A4 effects. Avoid.
  • Hepatically cleared drugs at therapeutic dose: Add hepatic load on top of cholestatic baseline. Avoid where possible.
  • Hormonal contraceptives: No clinical interaction at typical dose. Not relevant for the user.
  • Levothyroxine: AAS may alter thyroid binding globulin and free T4 levels modestly. Recheck TSH if both running.
▸ Pharmacogenomics

Limited specific data. The user's June 2026 23andMe + bloodwork won't have a specific Dianabol pharmacogenomic flag. Indirect:

  • CYP3A4 ultra-rapid or poor metabolizer variants could shift methandienone clearance, but the variability is small relative to the dose ranges UGL product introduces.
  • UGT1A1 variants (Gilbert's syndrome, ~5-10% population) — already-elevated unconjugated bilirubin baseline; even mild cholestatic stress from Dianabol could push into clinically apparent jaundice faster.
  • HLA-B alleles — emerging evidence that DILI susceptibility for some drug classes has HLA association; not yet specific for AAS.
  • 5α-reductase (SRD5A2) variants — irrelevant for Dianabol since it's a poor 5α-reductase substrate.

For the user: No specific pharmacogenomic switch flips this from SKIP-AT-20 to anything else.

▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Legitimate US pharmacy N/A — — Zero retail supply chain since 1985 FDA revocation. No prescriber can write Dianabol in the US.
Underground lab (UGL) Various tablet vendors $0.50-2.00 / 10 mg tab Low-Medium Counterfeit + mislabeling endemic; substitution with methyltestosterone or oxymetholone documented in independent assays.
International gray-market pharmacy Russia, India, Mexico, Eastern Europe Variable Medium Pharmaceutical-grade methandienone (Naposim, Anabol) sometimes available; import to US is felony controlled-substance importation.
Compounding pharmacy Not available — — Schedule III; no compounding pathway in US.
Veterinary supply N/A — — Methandienone is not a veterinary product.

For the user, none of these paths are recommended. Schedule III possession is a federal felony. UGL tablets carry counterfeit + dosing + contamination risk. International gray-market import is import-illegality. The compound is structurally inappropriate for the user regardless of source.

Cost estimate (academic only): A 4-6 week kickstart cycle at 20-30 mg/day = 28-45 days × 25 mg = ~700-1100 mg total = ~70-110 tabs of 10 mg = $35-220 UGL. Trivial compared to the cost of a hepatic injury, an athletic commission failure, or a career-ending sanction.

▸ Biomarkers to track (deep)

(For documentation only. The user's biomarker plan does not include monitoring during Dianabol use because there is no Dianabol use planned.)

If a hypothetical AAS-using user wanted a defensible monitoring plan:

Baseline (before any cycle):

  • ALT, AST, GGT, alkaline phosphatase, total + direct bilirubin
  • Lipid panel — HDL-C, LDL-C, total cholesterol, triglycerides
  • CBC with differential — hemoglobin, hematocrit
  • CMP — creatinine, eGFR, fasting glucose
  • HbA1c
  • Total + free testosterone, LH, FSH, sensitive estradiol, SHBG, prolactin
  • BP — at-home monitoring, 7-day average
  • Resting HR
  • hsCRP

On cycle (week 2, week 4, week 6 if extended):

  • ALT, AST, bilirubin, GGT — primary safety panel
  • Lipid panel
  • CBC (hematocrit watch >52%)
  • BP weekly at home
  • Symptom log — cholestasis signals (jaundice, pruritus, dark urine, RUQ pain)

Post-cycle (week 2, week 6, week 12):

  • Full baseline panel + LH/FSH for HPG-axis recovery monitoring
  • Lipid panel — should normalize within 8-12 weeks
  • Liver panel — should normalize within 4-8 weeks
  • If anything fails to normalize by week 12, escalate to hepatology + endocrinology

Stop signs requiring immediate cessation:

  • ALT or AST >5x ULN, or any jaundice
  • Bilirubin elevation with cholestatic pattern (GGT high, AlkPhos high)
  • Pruritus without rash + dark urine + light stool — classic cholestasis triad
  • Sustained BP >150/95
  • Hematocrit >55%
  • Severe gyno onset
  • Mood instability beyond tolerance
▸ Controversies / open debates Live debate

  1. Did Dianabol "win" the 1960 Rome Olympics weightlifting? No — the US team lost to the Soviets despite Ziegler's Dianabol intervention. The Soviets were running testosterone preparations. The narrative that 1960 was a "Dianabol vs. nothing" event is American mythology; it was actually "Dianabol vs. testosterone," and the older compound won. This matters for understanding why the AAS arms race kept escalating after 1960 rather than stopping.

  2. The "safe Dbol cycle" claim. Bodybuilding forum culture sometimes promotes "Dbol can be safe at 20 mg/day for 4 weeks with TUDCA + NAC." There is no human RCT supporting this claim. Hepatotoxicity is a structural class effect; harm-reduction adjuncts narrow the risk envelope but don't eliminate it. The honest framing is "lower-risk than 50 mg/day for 8 weeks unsupported," not "safe."

  3. Kickstart-vs-no-kickstart debate. Some modern bodybuilding protocols drop the oral kickstart entirely and run injectable-only (T-enanthate or T-cypionate from week 1). The argument: the 4-week front-end strength surge from Dianabol is largely water + glycogen and reverses post-cycle, while the injectable-only path avoids the hepatic load entirely. For the user, this is academic — neither path is indicated. For modern bodybuilding, injectable-only is widely considered the cleaner default, with Dianabol kickstarts being increasingly seen as a 1990s holdover.

  4. Long-term cardiovascular risk. Modern AAS-cohort studies (HAARLEM, Smit 2021; Cureus 2025 systemic-effects review; MDPI IJMS 2025 cardiovascular review) document cumulative cardiomyopathy, LV hypertrophy, accelerated atherosclerosis in chronic AAS users. Whether a single 4-6 week Dianabol kickstart contributes meaningfully to lifetime CV risk is unresolved — the bodybuilding-cohort data is dominated by users running multiple compounds for years, not single-cycle users. Honest framing: the per-cycle CV risk is modest; the cumulative-career CV risk is real and well-documented.

  5. Ziegler's later denunciation. Dr. John Ziegler, who introduced Dianabol to American athletes, publicly condemned AAS use by 1967 and attributed his own cardiac complications partly to his self-experimentation. He died in 1983 — the same year Ciba pulled Dianabol. This piece of history matters: the inventor-popularizer of American AAS use, looking back at his own career, said it wasn't worth it. That's a "considered judgment from inside" that few drug classes have on record.

  6. Modern UGL Dianabol — is it actually methandienone? Independent assays of UGL Dianabol products historically show frequent under-dosing, over-dosing, and substitution (sometimes contains methyltestosterone or oxymetholone instead of methandienone). Without third-party HPLC, you don't know what you took. This is a separate harm category on top of the structural pharmacology.

▸ Verdict change log
  • 2026-05-10 — Initial verdict: SKIP-AT-20 at HIGH confidence. For a 20yo MMA athlete + business owner with intact HPG axis at peak endogenous testosterone, brain-priority archetype: zero medical indication, hepatotoxicity is the dominant concern, water retention is a combat-sport liability, WADA + state athletic commission ban makes positive test career-ending, Schedule III legality risk, UGL counterfeit risk, and most "gain" is water/glycogen reversing post-cycle. Verdict would only flip in counterfactuals (medically diagnosed catabolic-wasting state with injectable T contraindicated) that are not on any realistic horizon.
▸ Open questions / gaps Open

  1. Per-cycle vs. cumulative CV risk. Most modern AAS-cohort cardiovascular damage data is from chronic high-dose users running multiple compounds. The CV signature of a single 4-6 week Dianabol kickstart in an otherwise healthy user is undercharacterized. Probably modest, but the literature is thin.

  2. TUDCA + NAC efficacy in AAS-specific context. Animal + cholestatic-disease human data support both. No human RCT in AAS users specifically. Bodybuilding-culture consensus has converged on the combination as the harm-reduction floor; that consensus is not RCT-supported.

  3. Long-term metabolite (LTM) detection windows for tested athletes. Modern WADA labs target methandienone LTMs out to 4-6+ months post-discontinuation. The exact ceiling in a real-world high-cardio combat athlete is not well-published. Zero-tolerance for tested athletes — assume detectability for 6 months.

  4. Persistent hypogonadism risk after a single kickstart cycle. Most users recover HPG function within 12 weeks. A small fraction develops persistent secondary hypogonadism. Per-cycle probability of permanent HPG damage is unclear — bodybuilding-forum reports range 1-5%; rigorous data is absent.

  5. Underground-lab assay reliability in 2026. Independent third-party assay culture (Anabolic Lab, Janoshik) has improved over the past decade. UGL product is closer to label-claim than it was in the 1990s. Still nowhere near pharmaceutical-grade reliability, and for a Schedule III compound with no Rx pathway, the UGL supply chain is the only option.

References

Anabolic androgenic steroid-induced liver injury: An update — Niedfeldt 2022 / PMC9331524

pmc.ncbi.nlm.nih.gov · 2022

modern review of AAS hepatotoxicity mechanisms

View Study

Anabolic Steroid-Induced Cholestatic Liver Injury — PMC9426951

pmc.ncbi.nlm.nih.gov

bland cholestasis mechanism review

View Study

Anabolic androgenic steroid-induced hepatotoxicity — Bond 2016 / PubMed 27372877

pubmed.ncbi.nlm.nih.gov · 2016

mechanistic review

View Study

Hepatic effects of 17α-alkylated anabolic-androgenic steroids — Schoepe 2001 / PubMed 11366381

pubmed.ncbi.nlm.nih.gov · 2001

structural-class mechanism

View Study

Effect of methandrostenolone on blood lipids and liver function tests — Rozman 1971 / PubMed 4866087 / PMC1923870

pmc.ncbi.nlm.nih.gov · 1971

earliest robust documentation of HDL crash, LDL elevation, ALT/AST rise

View Study

Metandienone — Wikipedia

en.wikipedia.org · 1958

primary reference; Ciba 1958 synthesis, 1960 US release, 1983 Ciba withdrawal, 1985 FDA revocation, regulatory history

View Source

John Bosley Ziegler — Wikipedia

en.wikipedia.org · 1958

1958-1959 introduction to Bill March + York Barbell, 1960 Rome Olympics administration, 1967 condemnation, 1983 death

View Source

Anabolic Steroids Control Act of 1990 — H.R. 4658, Public Law 101-647

congress.gov · 1990

places methandrostenolone into Schedule III of the CSA effective Feb 1991

View Source

Androgenic Steroids — LiverTox NCBI Bookshelf NBK548931

ncbi.nlm.nih.gov

class entry; methandrostenolone listed as prototypical 17α-alkylated agent with Likelihood A for clinically apparent liver injury

View Source

Hepatotoxicity associated with illicit use of AAS in doping — European Review

europeanreview.org

doping-context review

View Source

Latest research

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…